Loading data for ACAD — first visit, this takes a few seconds.

Alerta

ACADIA Pharmaceuticals In... (ACAD)

NasdaqGS: ACAD · Precio en tiempo real · USD

30.68

+0.50 (1.66%)

Al cierre: Aug 19, 2026, 3:25 PM

1.66% (1D)

No hay datos disponibles

Precio de compra	26.34
Capitalización de mercado	5.26B
Ingresos (TTM)	1.14B
Beneficio neto (TTM)	380.48M
Beta	0.84
EPS (TTM)	2.23
Ratio PER (TTM)	13.7
Adelante PE	34.38
P/B (TTM)	4.02
P/S (TTM)	4.59
Earnings Date	Nov 4, 2026

Precio de venta	35.06
Volumen	448,337
Volumen medio (20D)	1,617,537
Abierto	30.66
Anterior Cerrar	30.18
Rango del día	30.36 - 30.87
Rango de 52 semanas	19.69 - 30.87
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de ACAD

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like gr...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha May 27, 2004

Empleados 796

Bolsa de Valores NasdaqGS

Símbolo bursátil ACAD

Sitio web https://www.acadia.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de ACADIA Pharmaceuticals fueron 1.07B, un aumento de 11.87% en comparación con 957.8M del año anterior. Las ganancias fueron 391M, un aumento de 72.66%.

Estados financieros

Sorpresa de resultados

ACADIA Pharmaceuticals ha publicado sus resultados trimestrales en Aug 4, 2026:

Ingresos de $307.96M falla las estimaciones por $0, con 16.40% Crecimiento interanual.

EPS de 0.18 supera las estimaciones en 0.14, con 12.50% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que ACADIA Pharmaceuticals Inc. publique sus resultados el Nov 4, 2026, durante el horario de mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

6 días hace · MarketBeat

ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer’s Data

ACADIA Pharmaceuticals (NASDAQ:ACAD) outlined commercial expansion plans for its marketed therapies, DAYBUE and NUPLAZID, while highlighting upcoming clinical data for remlifanserin in Alzheimer’s dis...

1 semana hace · Motley Fool

Acadia Pharmaceuticals (ACAD) Q2 2026 Earnings Call Transcript

Revenue hit $308 million with 17% growth, driven by DAYBUE and NUPLAZID demand.

1 semana hace · Proactive

Immunic appoints Elena Ridloff to board of directors

Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named Elena Ridloff to its board of directors, the biotechnology company said Monday. Ridloff currently serves as CFO at Sionna Therapeutics. She previously hel...

1 semana hace · MT Newswires

Acadia Pharmaceuticals to Gain From Daybue, Nuplazid Growth; RADIANT Data Adds Risk, Morgan Stanley Says

Acadia Pharmaceuticals (ACAD) could benefit from wider Daybue use, steady Nuplazid growth, higher ca

1 semana hace · Simply Wall St.

Acadia Pharmaceuticals (ACAD) Stock Gets Fair Value Bump As Analysts Back Daybue Growth

ACADIA Pharmaceuticals has seen its fair value price target adjusted from US$31.80 to US$33.25 per share, reflecting updated assumptions around its business outlook. Recent analyst commentary generall...

Página 1 de 2